Equities

Delta 9 Cannabis Inc

Delta 9 Cannabis Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.03
  • Today's Change0.005 / 20.00%
  • Shares traded405.81k
  • 1 Year change-45.45%
  • Beta1.4225
Data delayed at least 15 minutes, as of May 03 2024 20:46 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Delta 9 Cannabis Inc. is a Canada-based vertically integrated cannabis company. The Company operates through three segments: Wholesale Cannabis, Retail Cannabis and Merchandise and Devices, and Business to Business. The Company sells cannabis products through its wholesale and retail sales channels and sells its cannabis growing pods to other businesses. Its cannabis products include dried cannabis and pre-rolled joints. Its edibles and vapes include vape pens and concentrates, edibles, and drinkables. The Company, through its wholly owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis products and operates a 95,000-square-foot Health Canada licensed production facility in Winnipeg, Manitoba, Canada. It also owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. It is focused on producing and selling cannabis oils, extracts, and derivative products.

  • Revenue in CAD (TTM)71.07m
  • Net income in CAD-17.52m
  • Incorporated2001
  • Employees200.00
  • Location
    Delta 9 Cannabis IncOsborne VillagePO Box 68096WINNIPEG R3L 2V9CanadaCAN
  • Phone+1 (204) 997-5328
  • Fax+1 (204) 997-5328
  • Websitehttps://www.delta9.ca/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Good Shroom Co Inc4.26m-35.66k6.09m----9.88--1.43-0.0007-0.00070.08520.01212.576.047.33---2.15---5.42--26.23---0.8368--1.01-4.800.0971--160.30--72.24------
Rakovina Therapeutics Inc0.00-2.61m6.31m----1.72-----0.0374-0.03740.000.05220.00-------46.38---47.48-------------28.520.267------6.39------
Voyageur Pharmaceuticals Ltd0.00-1.35m6.94m----4.41-----0.0101-0.01010.000.01140.00-------50.78-74.47-69.30-120.92--------0.4715-290.540.0248------20.21---11.81--
XORTX Therapeutics Inc0.00-2.95m7.30m3.00--1.15-----1.52-1.520.003.180.00-------24.19-35.42-26.94-40.37------------0.0025------72.04--7.91--
Delta 9 Cannabis Inc71.07m-17.52m7.85m200.00------0.1104-0.0997-0.09970.4129-0.03420.86863.3333.55355,326.70-20.33-13.74-52.07-23.3925.2926.99-23.41-17.980.1337-4.691.11--12.3956.5035.61---48.22--
Crescita Therapeutics Inc17.52m-1.99m8.40m78.00--0.4559--0.4796-0.0977-0.09770.86510.94320.66021.223.94---7.48-0.2457-9.42-0.305959.1563.41-11.33-0.35182.54--0.0625---25.521.05-330.39---1.58--
Khiron Life Sciences Corp16.14m-30.66m9.30m310.00--0.3205--0.5761-0.1674-0.16740.0850.12480.30781.333.9052,055.68-58.47---69.10--19.51---190.00--0.9133--0.0864--59.60---37.81------
CanadaBis Capital Inc20.91m3.27m9.66m--2.951.182.390.4620.02370.02370.15140.05920.97781.909.81--15.27-20.5527.30-54.8652.50--15.62-26.610.55097.880.4948--90.44--630.61--238.08--
Data as of May 03 2024. Currency figures normalised to Delta 9 Cannabis Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.